183 related articles for article (PubMed ID: 38228729)
21. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
23. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
[TBL] [Abstract][Full Text] [Related]
24. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
[TBL] [Abstract][Full Text] [Related]
26. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Carril-Ajuria L; Desnoyer A; Meylan M; Dalban C; Naigeon M; Cassard L; Vano Y; Rioux-Leclercq N; Chouaib S; Beuselinck B; Chabaud S; Barros-Monteiro J; Bougoüin A; Lacroix G; Colina-Moreno I; Tantot F; Boselli L; De Oliveira C; Fridman WH; Escudier B; Sautes-Fridman C; Albiges L; Chaput-Gras N
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640928
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Flippot R; Dalban C; Laguerre B; Borchiellini D; Gravis G; Négrier S; Chevreau C; Joly F; Geoffrois L; Ladoire S; Mahammedi H; Rolland F; Gross-Goupil M; Deluche E; Priou F; Laramas M; Barthélémy P; Narciso B; Houedé N; Culine S; Oudard S; Chenot M; Tantot F; Chabaud S; Escudier B; Albiges L
J Clin Oncol; 2019 Aug; 37(23):2008-2016. PubMed ID: 31194611
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
29. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
30. Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis.
Haaker L; Baldewijns M; De Wever L; Albersen M; Debruyne PR; Wynendaele W; De Meerleer G; Beuselinck B
Clin Genitourin Cancer; 2023 Aug; 21(4):442-451. PubMed ID: 36997468
[TBL] [Abstract][Full Text] [Related]
31. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
[TBL] [Abstract][Full Text] [Related]
34. Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.
Yang Y; Mori SV; Li M; Hinkley M; Parikh AB; Collier KA; Miah A; Yin M
Cancer Med; 2022 Apr; 11(7):1669-1677. PubMed ID: 35138046
[TBL] [Abstract][Full Text] [Related]
35. A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
Bando Y; Hinata N; Omori T; Fujisawa M
BMJ Open; 2019 Dec; 9(12):e030522. PubMed ID: 31826889
[TBL] [Abstract][Full Text] [Related]
36. Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
Courcier J; Dalban C; Laguerre B; Ladoire S; Barthélémy P; Oudard S; Joly F; Gravis G; Chevreau C; Geoffrois L; Deluche É; Rolland F; Topart D; Culine S; Négrier S; Mahammedi H; Tantot F; Jamet A; Escudier B; Flippot R; Albigès L
Eur Urol; 2021 Sep; 80(3):325-329. PubMed ID: 34103181
[TBL] [Abstract][Full Text] [Related]
37. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
[No Abstract] [Full Text] [Related]
38. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
[TBL] [Abstract][Full Text] [Related]
39. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
